In the majority of cases, the sentinel node is the only positive node in the axilla and completion ALND (cALND) is a futile procedure. However, refraining from cALND will lead to less accurate staging and, possibly, undertreatment. To help resolve this dilemma, we examined the clinical value of cALND in staging and determining adjuvant treatment.
In a retrospective cohort, all consecutive patients over a five-year period with primary breast cancer who received ALND were identified and grouped based on timing of ALND. Total nodal yield and positive lymph nodes were defined and factors with possible impact identified. In the case of cALND, N-status upstaging and possible impact on adjuvant treatment were studied in detail.
A total of 280 patients were selected of whom 204 underwent primary ALND (pALND) and 76 cALND. pALND resulted in a significantly higher total nodal yield and more positive nodes when compared to cALND (p = 0.003, and p < 0.001, respectively). Neoadjuvant chemotherapy (NAC) had no effect on total nodal yield (p = 0.413), but resulted in fewer positive nodes (p < 0.001). Due to the results of cALND, only 11 patients (14%) had upstaging of N-status. All these patients were advised more extensive adjuvant radiotherapy.
In the majority of patients, cALND does not lead to upstaging. cALND should be performed only after a careful discussion with the patient about the pros and cons of this procedure, and most probably only in the presence of multiple risk factors for axillary disease in the absence of systemic therapy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Samphao S, Eremin JM, El-Sheemy M, Eremin O (2008) Management of the axilla in women with breast cancer: current clinical practice and a new selective targeted approach. Ann Surg Oncol 15:1282–1296. https://doi.org/10.1245/s10434-008-9863-8
Gilissen F, Oostenbroek R, Storm R, Westenend P, Plaisier P (2008) Prevention of futile sentinel node procedures in breast cancer: ultrasonography of the axilla and fine-needle aspiration cytology are obligatory. Eur J Surg Oncol 34:497–500. https://doi.org/10.1016/j.ejso.2007.07.198
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdv298
Rao R, Euhus D, Mayo HG, Balch C (2013) Axillary node interventions in breast cancer a systematic review. JAMA 310:1385–1394. https://doi.org/10.1001/jama.2013.277804
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection versus no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA J Am Med Assoc 318:918–926. https://doi.org/10.1001/jama.2017.11470
Chakravorty A, Sanmugalingam N, Shrestha A, Thomee E, Rusby J, Roche N, MacNeill F (2011) Axillary nodal yields: a comparison between primary clearance and completion clearance after sentinel lymph node biopsy in the management of breast cancer. Eur J Surg Oncol 37:122–126. https://doi.org/10.1016/j.ejso.2010.10.005
Miltenburg DM, Miller C, Karamlou TB, Brunicardi FC (1999) Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 84:138–142. https://doi.org/10.1006/jsre.1999.5629
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575. https://doi.org/10.1001/jama.2011.90
Belmonte R, Messaggi-Sartor M, Ferrer M, Pont A, Escalada F (2018) Prospective study of shoulder strength, shoulder range of motion, and lymphedema in breast cancer patients from pre-surgery to 5 years after ALND or SLNB. Support Care Cancer 26:3277–3287. https://doi.org/10.1007/s00520-018-4186-1
Yan M, Abdi MA, Falkson C (2018) Axillary management in breast cancer patients: a comprehensive review of the key trials. Clin Breast Cancer 18:1251–1259. https://doi.org/10.1016/j.clbc.2018.08.002
Goyal A, Dodwell D (2015) POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol 27:692–695. https://doi.org/10.1016/j.clon.2015.07.005
Poodt IGM, Spronk PER, Vugts G, van Dalen T, Vrancken Peeters MTFD, Rots ML, Kuijer A, Nieuwenhuijzen GAP, Schipper RJ (2017) Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: A dutch population-based study in the ACOSOG-Z0011 and AMAROS era. Ann Surg 268:1084–1090. https://doi.org/10.1097/SLA.0000000000002440
Ahmed M, Jozsa F, Baker R, Rubio IT, Benson J, Douek M (2017) Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients. Breast Cancer Res Treat 166:329–336. https://doi.org/10.1007/s10549-017-4405-3
Krag DN, Weaver DL, Alex JC, Fairbank JT (1993) Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. https://doi.org/10.1016/0960-7404(93)90064-6
Collins M, O’Donoghue C, Sun W, Min Zhou J, Ma Z, Laronga C, Lee MC (2017) Use of axillary lymph node dissection (ALND) in patients with micrometastatic breast cancer. J. Surg. Res 215:55–59. https://doi.org/10.1016/j.jss.2017.03.039
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JHG, Orzalesi L, Bouma WH, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, Messina CGM, Bogaerts J, Rutgers EJT (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310. https://doi.org/10.1016/S1470-2045(14)70460-7
Byrne BE, Cutress RI, Gill J, Wise MH, Yiangou C, Agrawal A (2012) The axillary nodal harvest in breast cancer surgery is unchanged by sentinel node biopsy or the timing of surgery. Int J Breast Cancer. https://doi.org/10.1155/2012/467825
Olson JA, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2008) Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group trials Z0010 and Z0011. J Clin Oncol 26:3530–3535. https://doi.org/10.1200/JCO.2007.15.5630
Stitzenberg KB, Meyer AA, Stern SL, Cance WG, Calvo BF, Klauber-DeMore N, Kim HJ, Sansbury L, Ollila DW, Wood WC, Cox CE, McMasters KM (2003) Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg 237:607–612. https://doi.org/10.1097/00000658-200305000-00002
Swaminathan S, Reintgen M, Kerivan L, Reintgen E, Smith J, Reintgen D (2016) Extracapsular extension in the sentinel lymph node: guidelines for therapy. Clin Breast Cancer 16:65–68. https://doi.org/10.1016/j.clbc.2016.02.015
Baslaim MM, Al Malik OA, Al-Sobhi SS, Ibrahim E, Ezzat A, Ajarim D, Tulbah A, Chaudhary MA, Sorbris RA (2002) Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg 184:299–301. https://doi.org/10.1016/S0002-9610(02)00959-5
Neuman H, Carey LA, Ollila DW, Livasy C, Calvo BF, Meyer AA, Kim HJ, Meyers MO, Dees EC, Collichio FA, Sartor CI, Moore DT, Sawyer LR, Frank J, Klauber-DeMore N (2006) Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg 191:827–829. https://doi.org/10.1016/j.amjsurg.2005.08.041
Levine MN, Bramwell V, Abu-Zahra H, Goodyear MD, Arnold A, Findlay B, Skillings J, Gent M (1992) The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. Br J Cancer 65:130–132. https://doi.org/10.1038/bjc.1992.25
We would like to express our gratitude to Joost van Rosmalen, from the Department of Biostatistics, Erasmus MC, Rotterdam, for his assistance with the statistical analysis in our study.
This study did not receive any grants or funding.
Conflict of interest
The authors declare no conflicts of interest.
Consent was given for registration of medical data for anonymous research.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
van Bekkum, S., Kraima, A.C., Westenend, P.J. et al. The Dilemma After an Unforeseen Positive Sentinel Node in Primary Breast Cancer: Is Completion Axillary Dissection Necessary?. World J Surg (2020). https://doi.org/10.1007/s00268-020-05650-8